Co-morbidities in hidradenitis suppurativa
Research type
Research Study
Full title
Co-morbidities in hidradenitis suppurativa – cardiovascular disease and inflammatory bowel disease
IRAS ID
294497
Contact name
Niamh Kearney
Contact email
Sponsor organisation
St. Vincent's University Hospital
Duration of Study in the UK
1 years, 7 months, 25 days
Research summary
Hidradenitis suppurativa (HS) is a chronic cutaneous inflammatory disease associated with premature cardiovascular disease (CVD) and increased co-morbidities compared to the general population. The cause of this risk has not yet been established.
We aim to establish the rates of traditional and novel cardiovascular risk factors and clinical coronary disease in the HS population. We aim to identify principal risk factors facilitate screening and early intervention and minimise morbidity and mortality.
There is a two-fold increased risk of inflammatory bowel disease (IBD) in HS. Our further objective is to investigate the role of faecal calprotectin screening in patients with HS to facilitate early diagnosis and intervention.
This is a collaborative project between St. Vincent’s University Hospital Dublin and Belfast Health and Social Care Trust. All patients with HS will be eligible and offered recruitment. Patients will be assessed clinically with history, examination and use of verified disease instruments to determine severity. A thorough past medical history will be elicited along with assessment of cardiovascular risk factors.
Blood tests will be taken for traditional and new cardiovascular risk factors and we will predict the likelihood of CVD with the pooled cohort equation. We will determine resistance to insulin using the homeostatic model. Biopsies will be taken from an area of HS to detect levels of inflammatory cytokines. A subset of patients in Dublin will undergo computed tomography coronary angiography (CTCA).
In the IBD arm, all patients will complete a questionnaire and be offered a faecal calprotectin test. Assessment by a gastroenterologist will be offered to patients. We will quantify all results and confirmed IBD cases to generate a positive predictive value in screening.
REC name
North West - Preston Research Ethics Committee
REC reference
21/NW/0171
Date of REC Opinion
8 Jul 2021
REC opinion
Further Information Favourable Opinion